Advertisement
Correspondence

Authors' Reply

  • Peter J Hotez mail,

    To whom correspondence should be addressed. E-mail: mtmpjh@gwumc.edu

    Affiliation: The George Washington University, Department of Microbiology and Tropical Medicine, Washington, District of Columbia, United States of America

    X
  • David H Molyneux,

    Affiliation: Liverpool School of Tropical Medicine, Lymphatic Filariasis Support Centre, Liverpool, United Kingdom

    X
  • Alan Fenwick,

    Affiliation: Imperial College London, Infectious Disease Epidemiology, St. Mary's Campus, London, United Kingdom

    X
  • Eric Ottesen,

    Affiliation: Emory University, Rollins School of Public Health, Atlanta, Georgia, United States of America

    X
  • Sonia Ehrlich Sachs,
  • Jeffrey D Sachs

    Affiliation: Columbia University, The Earth Institute, New York, New York, United States of America

    X
  • Published: June 27, 2006
  • DOI: 10.1371/journal.pmed.0030284

About the Authors

Peter J Hotez
The George Washington University, Department of Microbiology and Tropical Medicine, Washington, District of Columbia, United States of America
David H Molyneux
Liverpool School of Tropical Medicine, Lymphatic Filariasis Support Centre, Liverpool, United Kingdom
Alan Fenwick
Imperial College London, Infectious Disease Epidemiology, St. Mary's Campus, London, United Kingdom
Eric Ottesen
Emory University, Rollins School of Public Health, Atlanta, Georgia, United States of America
Jeffrey D Sachs
Columbia University, The Earth Institute, New York, New York, United States of America

Corresponding Author

Email: mtmpjh@gwumc.edu

Competing Interests

PJH is partially supported by the Bill and Melinda Gates Foundation, Seattle, Washington, United States of America, through the Human Hookworm Vaccine Initiative of the Albert B. Sabin Vaccine Institute, Washington, District of Columbia, United States of America. He is an inventor on an international patent application (PCT/US02/33106; filed November 11, 2002) entitled “Hookworm Vaccine.” The patent was filed in the United States, Brazil, India, China, and Mexico. If awarded, the patent would belong to The George Washington University, with an exclusive license to the Human Hookworm Vaccine Initiative of the Albert B. Sabin Vaccine Institute, a nonprofit (501(c)3) organization devoted to increasing the use of vaccines worldwide. Because hookworm is a neglected disease afflicting the poorest of the poor in developing countries, a hookworm vaccine has no anticipated commercial value or income-generating potential. The rationale for filing a patent is to ensure that the vaccine is developed for those who need it in developing countries and to encourage vaccine manufacturers in developing countries to work with the Albert B. Sabin Vaccine Institute for manufacture of the hookworm vaccine. The first-generation hookworm vaccine, the Na-ASP-2 Hookworm Vaccine, was developed entirely in the nonprofit sector through the Human Hookworm Vaccine Initiative of the Albert B. Sabin Vaccine Institute. PJH is also co-chair of the Scientific Advisory Council of the Albert B. Sabin Vaccine Institute (he receives no compensation for this activity). DHM is partially supported by the United Kingdom Department for International Development and by GlaxoSmithKline, London, United Kingdom, and participates in the Mectizan Expert Committee/Albendazole Coordination meetings, which are supported by Merck, Whitehouse Station, New Jersey, United States of America, and by GlaxoSmithKline, London, United Kingdom. AF is director of the Schistosomiasis Control Initiative, which is supported by the Bill and Melinda Gates Foundation, Seattle, Washington, United States of America. EO is supported through the Task Force for Child Survival and Development and the Carter Center, Atlanta, Georgia, United States of America; by the Bill and Melinda Gates Foundation, Seattle, Washington, United States of America; by GlaxoSmithKline, London, United Kingdom; and by the Global Alliance to Eliminate Lymphatic Filariasis, Liverpool, United Kingdom. SES declares that she has no competing interests. JDS is partially supported by the United Nations, New York, New York, United States of America.